Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA)

INTRODUCTION: Lymphatic anomalies (LAs) refer to a group of diseases involving systemic dysplasia of lymphatic vessels. These lesions are classified as cystic lymphatic malformation (macrocystic, microcystic or mixed), generalized lymphatic anomaly, and Gorham–Stout disease. LAs occur mainly in chil...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozeki, Michio, Asada, Ryuta, Saito, Akiko M., Hashimoto, Hiroya, Fujimura, Takumi, Kuroda, Tatsuo, Ueno, Shigeru, Watanabe, Shoji, Nosaka, Shunsuke, Miyasaka, Mikiko, Umezawa, Akihiro, Matsuoka, Kentaro, Maekawa, Takanobu, Yamada, Yohei, Fujino, Akihiro, Hirakawa, Satoshi, Furukawa, Taizo, Tajiri, Tatsuro, Kinoshita, Yoshiaki, Souzaki, Ryota, Fukao, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society for Regenerative Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348766/
https://www.ncbi.nlm.nih.gov/pubmed/30705924
http://dx.doi.org/10.1016/j.reth.2018.12.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348766/
https://www.ncbi.nlm.nih.gov/pubmed/30705924
http://dx.doi.org/10.1016/j.reth.2018.12.001

Ejemplares similares